Manru Ning

Manru Ning

Auto-generated profile, based on publicly available information

Manru Ning

Yunnan Characteristic Plant Extraction Laboratory Co., Ltd. Kunming Yunnan China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2025 in Health Science Reports
Verified
Journal Article
Open access
XZXinxuan Zhang
Xinxuan Zhang
MNManru Ning
Manru Ning
MLMengqing Lin
Mengqing Lin
QTQi Tang
Qi Tang
YLYihuai Liang
Yihuai Liang
XXXiaoke Xu
Xiaoke Xu
Background and Aims: Skin aging is a common concern among individuals, and laser treatments are recognized as one of the most effective approaches to mitigate the aging process. The study aims to compare a multibeneficial formula serum versus a blank formulation in achieving maximum efficacy following a single treatment of nonablative fractional laser for facial skin rejuvenation.Methods: This study was a double‐blind, split‐face, monocentric, randomized clinical trial in China (September 24, 2023–March 07, 2024), and 37 patients seeking the Fotona 4D laser treatment for aging‐related facial changes were enrolled. After one full‐face laser treatment, each patient applied the test serum to one side and the blank formulation to the other, randomly, twice daily for 28 days. Two dermatologists assessed facial skin quality and aging signs at baseline and Day 0 (D0, immediately after the laser treatment), D3, D7, D14, and D28. Noninvasive measurement and self‐assessment questionnaires were also administered at each visit. According to the types of variables, appropriate statistical tests, including the Friedman test, ANOVA test, and Wilcoxon signed‐rank test, were used to examine the within‐groups or between‐groups differences.Results: Thirty‐three women, aged 35–49 years, completed the study. After 28 days of the test serum application, the visual clinical scores rated by investigators showed more significantly beneficial changes on the test side than those on the control. More significant improvements in index parameters for the test sides were also found both in wrinkles with a 21.14% decrease of SEw value from the baseline and in elasticity with a 14.99% decrease of R2 value, while the corresponding reductions were 3.83% for SEw and 4.10% for R2 found on the control sides. The reduction of the nasolabial folds area proportion, analyzed by Primos, was 10.61% on the test sides and 3.39% on the control. No adverse events were reported.Conclusion: The serum with a multi‐beneficial composition can contribute to achieving a more significant and sustainable efficacy after the Fotona 4D treatment in skin rejuvenation improvement.ClinicalTrials.gov ID: NCT06140628.

5 May 2026 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
PDF file
YHYixuan He
Yixuan He
MNManru Ning
Manru Ning
FWFeifei Wang
Feifei Wang
YLYihuai Liang
Yihuai Liang
SYShuxian Yan
Shuxian Yan
Background: In recent years, skin photoaging has received increasing attention, and laser therapy has become the most commonly used treatment due to its safety and efficacy; emerging evidence suggests that adjunctive “integrated skincare” may enhance treatment benefits by reducing post‐procedural reactions and supporting skin barrier repair. Objective: The split‐face, double‐blind, randomized, placebo‐controlled, monocentric clinical trial was conducted to validate the potential efficacy of anti‐photoaging and skin repair of a multifunctional serum formulation following a one‐session therapy of 1064‐nm picosecond Nd:YAG laser. Methods: A total of twenty‐four participants requesting picosecond laser therapy to address age‐associated facial alterations were recruited for the study. Following a two‐week washout period, participants underwent a single laser session on Day 1 (T1d) and applied either the multi‐beneficial serum or the placebo to the designated facial side twice daily for eight weeks. Their facial skin manifestations were assessed by two dermatologists at baseline, T0, T15d, T29d, and T57d, and the Symptom Score Reduction Index (SSRI) was analyzed later. Non‐invasive measurements and self‐assessments were also administered at each visit. Results: Twenty‐four women aged 30–48 years completed the trial. The scores for all other manifestations of skin photoaging, with the exception of coarse wrinkles, decreased on both the test and control sides throughout follow‐up. Based on SSRI values for individual photoaging signs, clinical efficacy rates for the test sides were superior to their counterparts. Regarding skin barrier function, decreasing transepidermal water loss and increasing stratum corneum hydration were observed on the test side during the period of recovery, with significant intergroup differences on T29d and T57d. Skin tone indicators (erythema index, melanin index, and tone evenness) rose shortly after the laser treatment and then declined on both sides; the magnitudes of reductions were greater on the test sides than on the control ones. Even though the improvement of skin surface evenness was found due to the therapy, the test sides exhibited more favorable changes than the controls, for instance, a reduction in the area proportion of crow's feet. No adverse events related to the test product were found during the study. Conclusion: The test serum enhanced the efficacy of 1064‐nm picosecond laser treatment for facial photoaging and supported skin barrier recovery.